Tesamorelin · Randomised human evidence. Tesamorelin: Randomised human evidence recorded as yes.

Semax / Selank · Randomised human evidence. Semax / Selank: Randomised human evidence recorded as none.

AOD-9604 · Randomised human evidence. AOD-9604: Randomised human evidence recorded as none.

GHK-Cu (injected) · Randomised human evidence. GHK-Cu (injected): Randomised human evidence recorded as topical only.

Epitalon · Randomised human evidence. Epitalon: Randomised human evidence recorded as none.

MOTS-c · Randomised human evidence. MOTS-c: Randomised human evidence recorded as none.

CJC-1295 · Randomised human evidence. CJC-1295: Randomised human evidence recorded as none.

Ipamorelin · Randomised human evidence. Ipamorelin: Randomised human evidence recorded as negative.

TB-500 · Randomised human evidence. TB-500: Randomised human evidence recorded as none.

BPC-157 · Randomised human evidence. BPC-157: Randomised human evidence recorded as none.

Petrelintide · Placebo-adjusted. Petrelintide: Placebo-adjusted recorded as -9.0 pp.

Petrelintide · Placebo arm. Petrelintide: Placebo arm recorded as -1.7 %.

Petrelintide · Weight change. Petrelintide: Weight change recorded as -10.7 %.

Petrelintide · Duration. Petrelintide: Duration recorded as 42 weeks.

Petrelintide · Participants. Petrelintide: Participants recorded as 493.

Petrelintide · Pivotal trial. Petrelintide: Pivotal trial recorded as ZUPREME-1.

Petrelintide · Class. Petrelintide: Class recorded as Long-acting amylin analogue.

VK2735 (oral) · Placebo-adjusted. VK2735 (oral): Placebo-adjusted recorded as -10.9 pp.

VK2735 (oral) · Placebo arm. VK2735 (oral): Placebo arm recorded as -1.3 %.

VK2735 (oral) · Weight change. VK2735 (oral): Weight change recorded as -12.2 %.

VK2735 (oral) · Duration. VK2735 (oral): Duration recorded as 13 weeks.

VK2735 (oral) · Participants. VK2735 (oral): Participants recorded as 280.

VK2735 (oral) · Pivotal trial. VK2735 (oral): Pivotal trial recorded as VENTURE-Oral.

VK2735 (oral) · Class. VK2735 (oral): Class recorded as Dual GLP-1 / GIP agonist.

Survodutide · Placebo-adjusted. Survodutide: Placebo-adjusted recorded as -7.6 pp.

Survodutide · Placebo arm. Survodutide: Placebo arm recorded as -5.4 %.

Survodutide · Weight change. Survodutide: Weight change recorded as -13.0 %.

Survodutide · Duration. Survodutide: Duration recorded as 76 weeks.

Survodutide · Participants. Survodutide: Participants recorded as 725.

Survodutide · Pivotal trial. Survodutide: Pivotal trial recorded as SYNCHRONIZE-1.

Survodutide · Class. Survodutide: Class recorded as Dual glucagon + GLP-1 agonist.

MariTide · Placebo-adjusted. MariTide: Placebo-adjusted recorded as -13.7 pp.

MariTide · Placebo arm. MariTide: Placebo arm recorded as -2.5 %.

MariTide · Weight change. MariTide: Weight change recorded as -16.2 %.

MariTide · Duration. MariTide: Duration recorded as 52 weeks.

MariTide · Participants. MariTide: Participants recorded as 592.

MariTide · Class. MariTide: Class recorded as GIP receptor antagonist conjugated to a GLP-1 agonist.

Aleniglipron · Weight change. Aleniglipron: Weight change recorded as -16.3 %.

Aleniglipron · Duration. Aleniglipron: Duration recorded as 44 weeks.

Aleniglipron · Participants. Aleniglipron: Participants recorded as 85.

Aleniglipron · Pivotal trial. Aleniglipron: Pivotal trial recorded as ACCESS II.

Aleniglipron · Class. Aleniglipron: Class recorded as Oral small-molecule GLP-1 agonist.

Bimagrumab + semaglutide · Weight change. Bimagrumab + semaglutide: Weight change recorded as -22.1 %.

Bimagrumab + semaglutide · Duration. Bimagrumab + semaglutide: Duration recorded as 72 weeks.

Bimagrumab + semaglutide · Participants. Bimagrumab + semaglutide: Participants recorded as 507.

Bimagrumab + semaglutide · Pivotal trial. Bimagrumab + semaglutide: Pivotal trial recorded as BELIEVE.

Bimagrumab + semaglutide · Class. Bimagrumab + semaglutide: Class recorded as Anti-activin receptor antibody, muscle-sparing, combined with a GLP-1.

Amycretin · Placebo-adjusted. Amycretin: Placebo-adjusted recorded as -24.0 pp.

Amycretin · Placebo arm. Amycretin: Placebo arm recorded as 2.0 %.

Amycretin · Weight change. Amycretin: Weight change recorded as -22.0 %.

Amycretin · Duration. Amycretin: Duration recorded as 36 weeks.

Amycretin · Participants. Amycretin: Participants recorded as 125.

Amycretin · Class. Amycretin: Class recorded as Single molecule acting on GLP-1 and amylin receptors.

CagriSema · Placebo-adjusted. CagriSema: Placebo-adjusted recorded as -17.4 pp.

CagriSema · Placebo arm. CagriSema: Placebo arm recorded as -3.0 %.

CagriSema · Weight change. CagriSema: Weight change recorded as -20.4 %.

CagriSema · Duration. CagriSema: Duration recorded as 68 weeks.

CagriSema · Participants. CagriSema: Participants recorded as 3 417.

CagriSema · Pivotal trial. CagriSema: Pivotal trial recorded as REDEFINE 1.

CagriSema · Class. CagriSema: Class recorded as Amylin analogue + GLP-1 agonist.

Retatrutide · Placebo-adjusted. Retatrutide: Placebo-adjusted recorded as -26.1 pp.

Retatrutide · Placebo arm. Retatrutide: Placebo arm recorded as -2.2 %.

Retatrutide · Weight change. Retatrutide: Weight change recorded as -28.3 %.

Retatrutide · Duration. Retatrutide: Duration recorded as 80 weeks.

Retatrutide · Participants. Retatrutide: Participants recorded as 2 339.

Retatrutide · Pivotal trial. Retatrutide: Pivotal trial recorded as TRIUMPH-1.

Retatrutide · Class. Retatrutide: Class recorded as Triple GLP-1 / GIP / glucagon agonist.

Ecnoglutide · TGA. Ecnoglutide: TGA position recorded as not approved.

Ecnoglutide · Canada. Ecnoglutide: Canada position recorded as not approved.

Ecnoglutide · PMDA. Ecnoglutide: PMDA position recorded as not approved.

Ecnoglutide · ANVISA. Ecnoglutide: ANVISA position recorded as not approved.

Ecnoglutide · MHRA. Ecnoglutide: MHRA position recorded as not approved.

Ecnoglutide · EMA. Ecnoglutide: EMA position recorded as not approved.

Ecnoglutide · FDA. Ecnoglutide: FDA position recorded as not approved.

Ecnoglutide · Duration. Ecnoglutide: Duration recorded as 48 weeks.

Ecnoglutide · Pivotal trial. Ecnoglutide: Pivotal trial recorded as SLIMMER.

Ecnoglutide · Placebo-adjusted. Ecnoglutide: Placebo-adjusted recorded as -15.1 pp.

Ecnoglutide · Placebo arm. Ecnoglutide: Placebo arm recorded as -0.3 %.

Ecnoglutide · Weight change. Ecnoglutide: Weight change recorded as -15.4 %.

Ecnoglutide · Dose. Ecnoglutide: Dose recorded as 2.4 mg weekly.

Ecnoglutide · Route. Ecnoglutide: Route recorded as Injection, weekly.

Ecnoglutide · Class. Ecnoglutide: Class recorded as cAMP-biased GLP-1 receptor agonist.

Ecnoglutide · Brand. Ecnoglutide: Brand recorded as Ecnoglutide (brand not disclosed).

Mazdutide · TGA. Mazdutide: TGA position recorded as not approved.

Mazdutide · Canada. Mazdutide: Canada position recorded as not approved.

Mazdutide · PMDA. Mazdutide: PMDA position recorded as not approved.

Mazdutide · ANVISA. Mazdutide: ANVISA position recorded as not approved.

Mazdutide · MHRA. Mazdutide: MHRA position recorded as not approved.

Mazdutide · EMA. Mazdutide: EMA position recorded as not approved.

Mazdutide · FDA. Mazdutide: FDA position recorded as not approved.

Mazdutide · Duration. Mazdutide: Duration recorded as 48 weeks.

Mazdutide · Pivotal trial. Mazdutide: Pivotal trial recorded as GLORY-1.

Mazdutide · Placebo-adjusted. Mazdutide: Placebo-adjusted recorded as -14.3 pp.

Mazdutide · Placebo arm. Mazdutide: Placebo arm recorded as -0.5 %.

Mazdutide · Weight change. Mazdutide: Weight change recorded as -14.8 %.

Mazdutide · Dose. Mazdutide: Dose recorded as 4 mg or 6 mg weekly.

Mazdutide · Route. Mazdutide: Route recorded as Injection, weekly.

Mazdutide · Class. Mazdutide: Class recorded as Dual glucagon + GLP-1 receptor agonist.

Mazdutide · Brand. Mazdutide: Brand recorded as Xin Er Mei (信尔美).

Metreleptin · TGA. Metreleptin: TGA position recorded as not approved.

Metreleptin · Canada. Metreleptin: Canada position recorded as not approved.

Metreleptin · NMPA. Metreleptin: NMPA position recorded as not approved.

Metreleptin · PMDA. Metreleptin: PMDA position recorded as approved.

Metreleptin · ANVISA. Metreleptin: ANVISA position recorded as not approved.

Metreleptin · MHRA. Metreleptin: MHRA position recorded as approved.

Metreleptin · Participants. Metreleptin: Participants recorded as 107.

Metreleptin · Pivotal trial. Metreleptin: Pivotal trial recorded as NIH open-label cohort.

Metreleptin · Dose. Metreleptin: Dose recorded as Up to 10 mg daily.

Metreleptin · Route. Metreleptin: Route recorded as Injection, daily.

Metreleptin · Class. Metreleptin: Class recorded as Recombinant leptin analogue.

Metreleptin · Brand. Metreleptin: Brand recorded as Myalept (US) / Myalepta (EU).

Setmelanotide · TGA. Setmelanotide: TGA position recorded as not approved.

Setmelanotide · Canada. Setmelanotide: Canada position recorded as not approved.

Setmelanotide · NMPA. Setmelanotide: NMPA position recorded as not approved.

Setmelanotide · PMDA. Setmelanotide: PMDA position recorded as not approved.

Setmelanotide · ANVISA. Setmelanotide: ANVISA position recorded as not approved.

Setmelanotide · MHRA. Setmelanotide: MHRA position recorded as approved.

Setmelanotide · Duration. Setmelanotide: Duration recorded as 52 weeks.

Setmelanotide · Participants. Setmelanotide: Participants recorded as 142.

Setmelanotide · Pivotal trial. Setmelanotide: Pivotal trial recorded as TRANSCEND.

Setmelanotide · Placebo-adjusted. Setmelanotide: Placebo-adjusted recorded as -18.4 pp.

Setmelanotide · Placebo arm. Setmelanotide: Placebo arm recorded as 2.6 %.

Setmelanotide · Weight change. Setmelanotide: Weight change recorded as -15.8 %.

Setmelanotide · Dose. Setmelanotide: Dose recorded as Titrated by age and weight, up to 3 mg daily.

Setmelanotide · Route. Setmelanotide: Route recorded as Injection, daily.

Setmelanotide · Class. Setmelanotide: Class recorded as MC4R agonist.

Setmelanotide · Brand. Setmelanotide: Brand recorded as Imcivree.

Phentermine · TGA. Phentermine: TGA position recorded as approved.

Phentermine · Canada. Phentermine: Canada position recorded as approved.

Phentermine · NMPA. Phentermine: NMPA position recorded as not approved.

Phentermine · PMDA. Phentermine: PMDA position recorded as not approved.

Phentermine · ANVISA. Phentermine: ANVISA position recorded as not approved.

Phentermine · MHRA. Phentermine: MHRA position recorded as not approved.

Phentermine · EMA. Phentermine: EMA position recorded as not approved.

Phentermine · Dose. Phentermine: Dose recorded as 37.5 mg daily.

Phentermine · Route. Phentermine: Route recorded as Tablet, daily.

Phentermine · Class. Phentermine: Class recorded as Sympathomimetic amine anorectic.

Phentermine · Brand. Phentermine: Brand recorded as Adipex-P, Lomaira, Duromine.

Orlistat · Canada. Orlistat: Canada position recorded as approved.

Orlistat · NMPA. Orlistat: NMPA position recorded as approved.

Orlistat · ANVISA. Orlistat: ANVISA position recorded as approved.

Orlistat · Duration. Orlistat: Duration recorded as 208 weeks.

Orlistat · Participants. Orlistat: Participants recorded as 3 305.

Orlistat · Pivotal trial. Orlistat: Pivotal trial recorded as XENDOS.

Orlistat · Placebo-adjusted. Orlistat: Placebo-adjusted recorded as -2.4 pp.

Orlistat · Placebo arm. Orlistat: Placebo arm recorded as -2.8 %.

Orlistat · Weight change. Orlistat: Weight change recorded as -5.2 %.

Orlistat · Dose. Orlistat: Dose recorded as 120 mg with each fat-containing meal; 60 mg over the counter.

Orlistat · Route. Orlistat: Route recorded as Capsule, three times daily.

Orlistat · Class. Orlistat: Class recorded as Gastrointestinal lipase inhibitor.

Orlistat · Brand. Orlistat: Brand recorded as Xenical (Rx) / alli (OTC).

Naltrexone / bupropion ER · Canada. Naltrexone / bupropion ER: Canada position recorded as approved.

Naltrexone / bupropion ER · NMPA. Naltrexone / bupropion ER: NMPA position recorded as not approved.

Naltrexone / bupropion ER · PMDA. Naltrexone / bupropion ER: PMDA position recorded as not approved.

Naltrexone / bupropion ER · ANVISA. Naltrexone / bupropion ER: ANVISA position recorded as not approved.

Naltrexone / bupropion ER · Duration. Naltrexone / bupropion ER: Duration recorded as 56 weeks.

Naltrexone / bupropion ER · Participants. Naltrexone / bupropion ER: Participants recorded as 1 074.

Naltrexone / bupropion ER · Pivotal trial. Naltrexone / bupropion ER: Pivotal trial recorded as COR-I.

Naltrexone / bupropion ER · Placebo-adjusted. Naltrexone / bupropion ER: Placebo-adjusted recorded as -4.1 pp.

Naltrexone / bupropion ER · Placebo arm. Naltrexone / bupropion ER: Placebo arm recorded as -1.3 %.

Naltrexone / bupropion ER · Weight change. Naltrexone / bupropion ER: Weight change recorded as -5.4 %.

Naltrexone / bupropion ER · Stopped for side effects. Naltrexone / bupropion ER: Stopped for side effects recorded as 24% vs 12% placebo — by far the highest of any approved agent.

Naltrexone / bupropion ER · Dose. Naltrexone / bupropion ER: Dose recorded as 32 mg / 360 mg daily.

Naltrexone / bupropion ER · Route. Naltrexone / bupropion ER: Route recorded as Tablet, twice daily.

Naltrexone / bupropion ER · Class. Naltrexone / bupropion ER: Class recorded as Opioid antagonist + aminoketone antidepressant.

Naltrexone / bupropion ER · Brand. Naltrexone / bupropion ER: Brand recorded as Contrave (US) / Mysimba (EU).

Phentermine / topiramate ER · TGA. Phentermine / topiramate ER: TGA position recorded as not approved.

Phentermine / topiramate ER · Canada. Phentermine / topiramate ER: Canada position recorded as not approved.

Phentermine / topiramate ER · NMPA. Phentermine / topiramate ER: NMPA position recorded as not approved.

Phentermine / topiramate ER · PMDA. Phentermine / topiramate ER: PMDA position recorded as not approved.

Phentermine / topiramate ER · ANVISA. Phentermine / topiramate ER: ANVISA position recorded as not approved.

Phentermine / topiramate ER · MHRA. Phentermine / topiramate ER: MHRA position recorded as not approved.

Phentermine / topiramate ER · Duration. Phentermine / topiramate ER: Duration recorded as 56 weeks.

Phentermine / topiramate ER · Participants. Phentermine / topiramate ER: Participants recorded as 2 487.

Phentermine / topiramate ER · Pivotal trial. Phentermine / topiramate ER: Pivotal trial recorded as CONQUER.

Phentermine / topiramate ER · Placebo-adjusted. Phentermine / topiramate ER: Placebo-adjusted recorded as -8.6 pp.

Phentermine / topiramate ER · Placebo arm. Phentermine / topiramate ER: Placebo arm recorded as -1.2 %.

Phentermine / topiramate ER · Weight change. Phentermine / topiramate ER: Weight change recorded as -9.8 %.

Phentermine / topiramate ER · Stopped for side effects. Phentermine / topiramate ER: Stopped for side effects recorded as Label reports only all-cause withdrawal of 31–40%, which is not comparable to other drugs' figures.

Phentermine / topiramate ER · Dose. Phentermine / topiramate ER: Dose recorded as 7.5/46 mg or 15/92 mg daily.

Phentermine / topiramate ER · Route. Phentermine / topiramate ER: Route recorded as Tablet, daily.

Phentermine / topiramate ER · Class. Phentermine / topiramate ER: Class recorded as Sympathomimetic + anticonvulsant combination.

Phentermine / topiramate ER · Brand. Phentermine / topiramate ER: Brand recorded as Qsymia.

Liraglutide 3.0 mg · Canada. Liraglutide 3.0 mg: Canada position recorded as approved.

Liraglutide 3.0 mg · NMPA. Liraglutide 3.0 mg: NMPA position recorded as not approved.

Liraglutide 3.0 mg · PMDA. Liraglutide 3.0 mg: PMDA position recorded as not approved.

Liraglutide 3.0 mg · ANVISA. Liraglutide 3.0 mg: ANVISA position recorded as approved.

Liraglutide 3.0 mg · Duration. Liraglutide 3.0 mg: Duration recorded as 56 weeks.

Liraglutide 3.0 mg · Participants. Liraglutide 3.0 mg: Participants recorded as 3 731.

Liraglutide 3.0 mg · Pivotal trial. Liraglutide 3.0 mg: Pivotal trial recorded as SCALE Obesity and Prediabetes.

Liraglutide 3.0 mg · Placebo-adjusted. Liraglutide 3.0 mg: Placebo-adjusted recorded as -5.4 pp.

Liraglutide 3.0 mg · Placebo arm. Liraglutide 3.0 mg: Placebo arm recorded as -2.6 %.

Liraglutide 3.0 mg · Weight change. Liraglutide 3.0 mg: Weight change recorded as -8.0 %.

Liraglutide 3.0 mg · Dose. Liraglutide 3.0 mg: Dose recorded as 3.0 mg daily.

Liraglutide 3.0 mg · Route. Liraglutide 3.0 mg: Route recorded as Injection, daily.

Liraglutide 3.0 mg · Class. Liraglutide 3.0 mg: Class recorded as GLP-1 receptor agonist.

Liraglutide 3.0 mg · Brand. Liraglutide 3.0 mg: Brand recorded as Saxenda + generics.

Orforglipron · TGA. Orforglipron: TGA position recorded as not approved.

Orforglipron · Canada. Orforglipron: Canada position recorded as not approved.

Orforglipron · NMPA. Orforglipron: NMPA position recorded as not approved.

Orforglipron · PMDA. Orforglipron: PMDA position recorded as not approved.

Orforglipron · ANVISA. Orforglipron: ANVISA position recorded as not approved.

Orforglipron · MHRA. Orforglipron: MHRA position recorded as not approved.

Orforglipron · EMA. Orforglipron: EMA position recorded as not approved.

Orforglipron · Duration. Orforglipron: Duration recorded as 72 weeks.

Orforglipron · Participants. Orforglipron: Participants recorded as 3 127.

Orforglipron · Pivotal trial. Orforglipron: Pivotal trial recorded as ATTAIN-1.

Orforglipron · Placebo-adjusted. Orforglipron: Placebo-adjusted recorded as -9.0 pp.

Orforglipron · Placebo arm. Orforglipron: Placebo arm recorded as -2.1 %.

Orforglipron · Weight change. Orforglipron: Weight change recorded as -11.1 %.

Orforglipron · Stopped for side effects. Orforglipron: Stopped for side effects recorded as 8% vs 3% placebo — the highest of the GLP-1 agents.

Orforglipron · Dose. Orforglipron: Dose recorded as Up to 17.2 mg daily, no food or water restrictions.

Orforglipron · Route. Orforglipron: Route recorded as Tablet, daily.

Orforglipron · Class. Orforglipron: Class recorded as Small-molecule (non-peptide) GLP-1 receptor agonist.

Orforglipron · Brand. Orforglipron: Brand recorded as Foundayo.

Tirzepatide · Duration. Tirzepatide: Duration recorded as 72 weeks.

Tirzepatide · Participants. Tirzepatide: Participants recorded as 2 539.

Tirzepatide · Pivotal trial. Tirzepatide: Pivotal trial recorded as SURMOUNT-1.

Tirzepatide · Placebo-adjusted. Tirzepatide: Placebo-adjusted recorded as -17.8 pp.

Tirzepatide · Placebo arm. Tirzepatide: Placebo arm recorded as -3.1 %.

Tirzepatide · Weight change. Tirzepatide: Weight change recorded as -20.9 %.

Tirzepatide · Stopped for side effects. Tirzepatide: Stopped for side effects recorded as 4.8–6.7% vs 3.4% placebo.

Tirzepatide · Dose. Tirzepatide: Dose recorded as 5, 10 or 15 mg weekly.

Tirzepatide · Route. Tirzepatide: Route recorded as Injection, weekly.

Tirzepatide · Class. Tirzepatide: Class recorded as Dual GIP + GLP-1 receptor agonist.

Tirzepatide · Brand. Tirzepatide: Brand recorded as Zepbound (US) / Mounjaro.

Semaglutide 25 mg, oral · TGA. Semaglutide 25 mg, oral: TGA position recorded as not approved.

Semaglutide 25 mg, oral · Canada. Semaglutide 25 mg, oral: Canada position recorded as not approved.

Semaglutide 25 mg, oral · NMPA. Semaglutide 25 mg, oral: NMPA position recorded as not approved.

Semaglutide 25 mg, oral · PMDA. Semaglutide 25 mg, oral: PMDA position recorded as not approved.

Semaglutide 25 mg, oral · ANVISA. Semaglutide 25 mg, oral: ANVISA position recorded as under review.

Semaglutide 25 mg, oral · Duration. Semaglutide 25 mg, oral: Duration recorded as 64 weeks.

Semaglutide 25 mg, oral · Participants. Semaglutide 25 mg, oral: Participants recorded as 307.

Semaglutide 25 mg, oral · Pivotal trial. Semaglutide 25 mg, oral: Pivotal trial recorded as OASIS 4.

Semaglutide 25 mg, oral · Placebo-adjusted. Semaglutide 25 mg, oral: Placebo-adjusted recorded as -12.0 pp.

Semaglutide 25 mg, oral · Placebo arm. Semaglutide 25 mg, oral: Placebo arm recorded as -2.0 %.

Semaglutide 25 mg, oral · Weight change. Semaglutide 25 mg, oral: Weight change recorded as -14.0 %.

Semaglutide 25 mg, oral · Stopped for side effects. Semaglutide 25 mg, oral: Stopped for side effects recorded as 7% vs 6% placebo.

Semaglutide 25 mg, oral · Dose. Semaglutide 25 mg, oral: Dose recorded as 25 mg daily, on an empty stomach with ≤120 ml water, then nothing for 30 minutes.

Semaglutide 25 mg, oral · Route. Semaglutide 25 mg, oral: Route recorded as Tablet, daily.

Semaglutide 25 mg, oral · Class. Semaglutide 25 mg, oral: Class recorded as GLP-1 receptor agonist.

Semaglutide 25 mg, oral · Brand. Semaglutide 25 mg, oral: Brand recorded as Wegovy tablets.

Semaglutide 7.2 mg · TGA. Semaglutide 7.2 mg: TGA position recorded as not approved.

Semaglutide 7.2 mg · Canada. Semaglutide 7.2 mg: Canada position recorded as not approved.

Semaglutide 7.2 mg · NMPA. Semaglutide 7.2 mg: NMPA position recorded as not approved.

Semaglutide 7.2 mg · PMDA. Semaglutide 7.2 mg: PMDA position recorded as not approved.

Semaglutide 7.2 mg · ANVISA. Semaglutide 7.2 mg: ANVISA position recorded as not approved.

Semaglutide 7.2 mg · Duration. Semaglutide 7.2 mg: Duration recorded as 72 weeks.

Semaglutide 7.2 mg · Pivotal trial. Semaglutide 7.2 mg: Pivotal trial recorded as STEP UP.

Semaglutide 7.2 mg · Placebo-adjusted. Semaglutide 7.2 mg: Placebo-adjusted recorded as -15.7 pp.

Semaglutide 7.2 mg · Placebo arm. Semaglutide 7.2 mg: Placebo arm recorded as -3.8 %.

Semaglutide 7.2 mg · Weight change. Semaglutide 7.2 mg: Weight change recorded as -19.5 %.

Semaglutide 7.2 mg · Dose. Semaglutide 7.2 mg: Dose recorded as 7.2 mg weekly, escalated from 2.4 mg.

Semaglutide 7.2 mg · Route. Semaglutide 7.2 mg: Route recorded as Injection, weekly.

Semaglutide 7.2 mg · Class. Semaglutide 7.2 mg: Class recorded as GLP-1 receptor agonist.

Semaglutide 7.2 mg · Brand. Semaglutide 7.2 mg: Brand recorded as Wegovy HD.

Semaglutide 2.4 mg · Duration. Semaglutide 2.4 mg: Duration recorded as 68 weeks.

Semaglutide 2.4 mg · Participants. Semaglutide 2.4 mg: Participants recorded as 1 961.

Semaglutide 2.4 mg · Pivotal trial. Semaglutide 2.4 mg: Pivotal trial recorded as STEP 1.

Semaglutide 2.4 mg · Placebo-adjusted. Semaglutide 2.4 mg: Placebo-adjusted recorded as -12.5 pp.

Semaglutide 2.4 mg · Placebo arm. Semaglutide 2.4 mg: Placebo arm recorded as -2.4 %.

Semaglutide 2.4 mg · Weight change. Semaglutide 2.4 mg: Weight change recorded as -14.9 %.

Semaglutide 2.4 mg · Stopped for side effects. Semaglutide 2.4 mg: Stopped for side effects recorded as 6.8% vs 3.2% placebo.

Semaglutide 2.4 mg · Dose. Semaglutide 2.4 mg: Dose recorded as 2.4 mg weekly after a 16-week escalation.

Semaglutide 2.4 mg · Route. Semaglutide 2.4 mg: Route recorded as Injection, weekly.

Semaglutide 2.4 mg · Class. Semaglutide 2.4 mg: Class recorded as GLP-1 receptor agonist.

Semaglutide 2.4 mg · Brand. Semaglutide 2.4 mg: Brand recorded as Wegovy.

Elixis-W · Units in the field. Elixis-W: Units in the field recorded as 0.

GR00T reference humanoid · Units in the field. GR00T reference humanoid: Units in the field recorded as 0.

GR00T reference humanoid · Price. GR00T reference humanoid: Price recorded as 100 000 USD.

GR00T reference humanoid · Degrees of freedom. GR00T reference humanoid: Degrees of freedom recorded as 75.

GR00T reference humanoid · Runtime. GR00T reference humanoid: Runtime recorded as 3.0 h.

GR00T reference humanoid · Weight. GR00T reference humanoid: Weight recorded as 68.0 kg.

GR00T reference humanoid · Height. GR00T reference humanoid: Height recorded as 183.0 cm.

Phoenix · Top speed. Phoenix: Top speed recorded as 1.34 m/s.

Phoenix · Payload. Phoenix: Payload recorded as 25.0 kg.

Phoenix · Weight. Phoenix: Weight recorded as 70.0 kg.

Phoenix · Height. Phoenix: Height recorded as 170.0 cm.

Shipyard welding humanoid · Units in the field. Shipyard welding humanoid: Units in the field recorded as 0.

Phantom MK1 · Price. Phantom MK1: Price recorded as 100 000 USD.

Phantom MK1 · Top speed. Phantom MK1: Top speed recorded as 1.70 m/s.

Phantom MK1 · Degrees of freedom. Phantom MK1: Degrees of freedom recorded as 19.

Phantom MK1 · Payload. Phantom MK1: Payload recorded as 20.0 kg.

Phantom MK1 · Weight. Phantom MK1: Weight recorded as 80.0 kg.

Phantom MK1 · Height. Phantom MK1: Height recorded as 175.0 cm.

Isaac 1 · Units in the field. Isaac 1: Units in the field recorded as 0.

Isaac 1 · Price. Isaac 1: Price recorded as 7 999 USD.

Isaac 1 · Degrees of freedom. Isaac 1: Degrees of freedom recorded as 21.

Isaac 1 · Runtime. Isaac 1: Runtime recorded as 8.0 h.

Isaac 1 · Height. Isaac 1: Height recorded as 175.0 cm.

HL Human · Units in the field. HL Human: Units in the field recorded as 0.

HL Human · Degrees of freedom. HL Human: Degrees of freedom recorded as 19.

Kaleido 9 · Units in the field. Kaleido 9: Units in the field recorded as 0.

Kaleido 9 · Payload. Kaleido 9: Payload recorded as 18.0 kg.

CLOiD · Units in the field. CLOiD: Units in the field recorded as 0.

CLOiD · Degrees of freedom. CLOiD: Degrees of freedom recorded as 14.

RB-Y1 · Top speed. RB-Y1: Top speed recorded as 1.50 m/s.

RB-Y1 · Degrees of freedom. RB-Y1: Degrees of freedom recorded as 20.

RB-Y1 · Payload. RB-Y1: Payload recorded as 3.0 kg.

RB-Y1 · Weight. RB-Y1: Weight recorded as 131.0 kg.

RB-Y1 · Height. RB-Y1: Height recorded as 140.0 cm.

4NE-1 · Top speed. 4NE-1: Top speed recorded as 1.39 m/s.

4NE-1 · Degrees of freedom. 4NE-1: Degrees of freedom recorded as 55.

4NE-1 · Payload. 4NE-1: Payload recorded as 20.0 kg.

4NE-1 · Weight. 4NE-1: Weight recorded as 80.0 kg.

4NE-1 · Height. 4NE-1: Height recorded as 180.0 cm.

CyberOne V2 · Units in the field. CyberOne V2: Units in the field recorded as 0.

CyberOne V2 · Degrees of freedom. CyberOne V2: Degrees of freedom recorded as 27.

T1 · Price. T1: Price recorded as 12 500 USD.

KUAVO-MY · Units in the field. KUAVO-MY: Units in the field recorded as 600.

KUAVO-MY · Degrees of freedom. KUAVO-MY: Degrees of freedom recorded as 40.

KUAVO-MY · Height. KUAVO-MY: Height recorded as 140.0 cm.

T1 · Price. T1: Price recorded as 5 999 USD.

T1 · Degrees of freedom. T1: Degrees of freedom recorded as 23.

T1 · Runtime. T1: Runtime recorded as 2.0 h.

T1 · Weight. T1: Weight recorded as 30.0 kg.

T1 · Height. T1: Height recorded as 118.0 cm.

Forerunner K2 · Price. Forerunner K2: Price recorded as 30 000 USD.

Forerunner K2 · Degrees of freedom. Forerunner K2: Degrees of freedom recorded as 52.

Forerunner K2 · Runtime. Forerunner K2: Runtime recorded as 8.0 h.

Forerunner K2 · Payload. Forerunner K2: Payload recorded as 15.0 kg.

Forerunner K2 · Weight. Forerunner K2: Weight recorded as 75.0 kg.

Forerunner K2 · Height. Forerunner K2: Height recorded as 175.0 cm.

GR-3 · Degrees of freedom. GR-3: Degrees of freedom recorded as 55.

GR-3 · Weight. GR-3: Weight recorded as 71.0 kg.

GR-3 · Height. GR-3: Height recorded as 165.0 cm.

T800 · Price. T800: Price recorded as 25 000 USD.

T800 · Top speed. T800: Top speed recorded as 3.00 m/s.

T800 · Degrees of freedom. T800: Degrees of freedom recorded as 29.

T800 · Runtime. T800: Runtime recorded as 3.0 h.

T800 · Weight. T800: Weight recorded as 75.0 kg.

T800 · Height. T800: Height recorded as 173.0 cm.

IRON (next-gen) · Units in the field. IRON (next-gen): Units in the field recorded as 0.

IRON (next-gen) · Degrees of freedom. IRON (next-gen): Degrees of freedom recorded as 84.

Galbot G1 · Units in the field. Galbot G1: Units in the field recorded as 900.

Galbot G1 · Runtime. Galbot G1: Runtime recorded as 10.0 h.

Galbot G1 · Payload. Galbot G1: Payload recorded as 5.0 kg.

Galbot G1 · Weight. Galbot G1: Weight recorded as 85.0 kg.

Galbot G1 · Height. Galbot G1: Height recorded as 173.0 cm.

Yuanzheng A2 Ultra · Units in the field. Yuanzheng A2 Ultra: Units in the field recorded as 8 400.

Yuanzheng A2 Ultra · Top speed. Yuanzheng A2 Ultra: Top speed recorded as 1.20 m/s.

Yuanzheng A2 Ultra · Degrees of freedom. Yuanzheng A2 Ultra: Degrees of freedom recorded as 40.

Yuanzheng A2 Ultra · Runtime. Yuanzheng A2 Ultra: Runtime recorded as 3.0 h.

Yuanzheng A2 Ultra · Payload. Yuanzheng A2 Ultra: Payload recorded as 2.0 kg.

Yuanzheng A2 Ultra · Weight. Yuanzheng A2 Ultra: Weight recorded as 69.0 kg.

Yuanzheng A2 Ultra · Height. Yuanzheng A2 Ultra: Height recorded as 169.0 cm.

Walker S2 · Units in the field. Walker S2: Units in the field recorded as 1 079.

Walker S2 · Degrees of freedom. Walker S2: Degrees of freedom recorded as 52.

Walker S2 · Payload. Walker S2: Payload recorded as 15.0 kg.

Walker S2 · Height. Walker S2: Height recorded as 176.0 cm.

H2 · Price. H2: Price recorded as 29 900 USD.

H2 · Top speed. H2: Top speed recorded as 2.00 m/s.

H2 · Degrees of freedom. H2: Degrees of freedom recorded as 31.

H2 · Payload. H2: Payload recorded as 7.0 kg.

H2 · Weight. H2: Weight recorded as 70.0 kg.

H2 · Height. H2: Height recorded as 180.0 cm.

G1 · Units in the field. G1: Units in the field recorded as 11 000.

G1 · Price. G1: Price recorded as 13 500 USD.

G1 · Degrees of freedom. G1: Degrees of freedom recorded as 23.

G1 · Runtime. G1: Runtime recorded as 2.0 h.

G1 · Payload. G1: Payload recorded as 2.0 kg.

G1 · Weight. G1: Weight recorded as 35.0 kg.

G1 · Height. G1: Height recorded as 132.0 cm.

NEO · Price. NEO: Price recorded as 20 000 USD.

NEO · Top speed. NEO: Top speed recorded as 1.40 m/s.

NEO · Degrees of freedom. NEO: Degrees of freedom recorded as 55.

NEO · Runtime. NEO: Runtime recorded as 4.0 h.

NEO · Payload. NEO: Payload recorded as 24.9 kg.

NEO · Weight. NEO: Weight recorded as 29.9 kg.

NEO · Height. NEO: Height recorded as 167.6 cm.

Atlas (electric) · Degrees of freedom. Atlas (electric): Degrees of freedom recorded as 56.

Atlas (electric) · Runtime. Atlas (electric): Runtime recorded as 4.0 h.

Atlas (electric) · Payload. Atlas (electric): Payload recorded as 30.0 kg.

Atlas (electric) · Weight. Atlas (electric): Weight recorded as 90.0 kg.

Atlas (electric) · Height. Atlas (electric): Height recorded as 190.0 cm.

Apollo 2 · Runtime. Apollo 2: Runtime recorded as 4.0 h.

Apollo 2 · Payload. Apollo 2: Payload recorded as 25.0 kg.

Apollo 2 · Weight. Apollo 2: Weight recorded as 72.6 kg.

Apollo 2 · Height. Apollo 2: Height recorded as 172.7 cm.

Digit v5 · Degrees of freedom. Digit v5: Degrees of freedom recorded as 16.

Digit v5 · Runtime. Digit v5: Runtime recorded as 20.0 h.

Digit v5 · Payload. Digit v5: Payload recorded as 16.0 kg.

Digit v5 · Height. Digit v5: Height recorded as 175.0 cm.

Optimus Gen 3 · Units in the field. Optimus Gen 3: Units in the field recorded as 0.

This page. First publication. Fourteen approved medicines, nine investigational compounds, six failures and ten unapproved peptides, each checked against regulator primary sources rather than press coverage.

Mazdutide · Ecnoglutide · Imcivree · Sevmia. Four dates downgraded after an independent verification pass. The Chinese approval dates for mazdutide and ecnoglutide are sponsor announcement dates, not regulator-confirmed — NMPA's database is not machine-accessible. Imcivree's European extension now shows the CHMP opinion date of 27 Mar 2026, because the Commission decision date is not published. And Sevmia is described as the first generic semaglutide indicated for weight management, not the first generic semaglutide in Canada, which it is not.

Semaglutide 7.2 mg (Wegovy HD). CORRECTION, same day as publication. We first recorded that the STEP UP placebo arm had never been published, and showed no placebo-adjusted figure. That was wrong: full tabular results have been posted on ClinicalTrials.gov all along, giving −19.5% against a −3.8% placebo arm — a placebo-adjusted difference of 15.7 points. The error came from relying on press coverage and the paywalled journal article instead of the registry. The row now carries the registry figures, and the note explains why the company's −20.7% headline differs.

Unitree. Listed on the Shanghai STAR Market at RMB 150.80/share, raising ~$904M. Closed the first day up 460% at ~RMB 342bn (~$50bn). First humanoid maker on China’s A-share market. Added IPO status; funding row rewritten.

Boston Dynamics / NEURA / UBTech / Weave. Full adversarial re-verification pass against primary sources (SEC EDGAR, HKEXnews, cninfo, issuer datasheets). Four cells changed: the Hyundai–Boston Dynamics ownership transfer is now recorded as agreed but unconfirmed rather than completed; NEURA’s 20 kg payload is labelled as an arms rating, since its own product page headlines a different 10–100 kg range; UBTech’s 1,079 units is labelled as full-size humanoids specifically; Weave’s 21 DoF is marked a claim, because it is our sum of Weave’s table rather than a figure Weave prints.

Unitree. Company claims an unnamed prototype reached 12.66 m/s and a 2 m standing jump. Logged as an unverified company claim; not added to the speed column of any shipping model.

Semaglutide. ANVISA approved the first Brazilian-made generic semaglutide (EMS, with Germed the same day). Brazil becomes the second country with a generic, after Canada.

LG Electronics. Announced a bipedal humanoid built on NVIDIA Isaac GR00T and Jetson Thor, to be unveiled Q1 2027. No model name or specs published. Added as a tracked programme with all spec cells empty.

Agility Robotics — Digit v5. Digit v5 unveiled. Runtime cell changed from “~4 h per charge” to “up to 20 h of work per day with fast charging”, tagged as a company claim. Added ISO-standard tool flange for swappable end effectors.

Market. H1 2026 shipment estimates published: AgiBot 8,400, Unitree 5,900, Galbot 900, UBTech 700, Leju 600. Galbot enters the global top three for the first time. Shipment column updated for five makers.

Dexterity — Mech. FedEx expanded autonomous trailer loading at the Hagerstown, MD hub from pilot to production scale. Status changed from “pilot” to “commercial”. Unit count still not disclosed.

AgiBot. Launched a Hong Kong IPO process with CITIC, CICC and Morgan Stanley as sponsors. A reported HK$156bn valuation is circulating and is NOT corroborated — we carry the HK$40–50bn cornerstone target instead.

Retatrutide. Lilly confirmed the filing has slipped to 2027. Recorded as a delay, not a failure — but it means the most effective compound on this page is at least two years from any pharmacy.

Unapproved peptides. An FDA advisory panel voted narrowly in favour of allowing six peptides to be compounded — BPC-157, KPV and TB-500 at 8–6 with one abstention, MOTS-c at 7–5 with two. Emideltide was rejected. This will be widely reported as legalisation. It is not: the votes are non-binding, rulemaking has not started, the last comparable cycle took over two years, and FDA's own briefing said the studies were too short and too small to establish safety or effectiveness.

Humanoid (UK). Raised $152M Series A at $1.35B post-money; $270M total. Europe’s first pure-play humanoid unicorn. Added to the list — note that no physical specification has ever been published for HMND 01.

Semaglutide 25 mg, oral · EMA. Semaglutide 25 mg, oral: EMA position recorded as approved · 15 Jul 2026.

Semaglutide 7.2 mg · EMA. Semaglutide 7.2 mg: EMA position recorded as approved · 15 Jul 2026.

Highlanders / Mitsubishi. Mitsubishi Motors to build the HL Human at its Kyoto plant on a repurposed engine line, up to 1,000 units/month from early 2027. Largest announced humanoid capacity outside China. Logged as a target, not a rate.

UBTech — UWORLD U1. Consumer humanoid launched from RMB 119,800 (~$16,500), 88 DoF. Company reported “over 13,361 units ordered” on day one and separately “2,100+ reservations in a week”. The two figures cannot both be right; both are carried as marketing claims and neither is in the units column.

Semaglutide. Health Canada authorised Apotex's Sevmia, the first generic semaglutide indicated for chronic weight management. Trade reporting attributes the early entry to a lapsed patent maintenance fee; Health Canada's own release does not say that, so we record it as reported rather than established.

Figure AI — Figure 03. BMW began a Figure 03 logistics sequencing project at Plant Spartanburg. Confirmed by BMW’s own press office. Unit count not disclosed by either party — units cell stays empty.

Agility Robotics. Going public via SPAC with Churchill Capital Corp XI at $2.5bn pre-money. Filings disclose 65,000+ operating hours across nine customer sites and a >$300M backlog. Press reports of “~1,000 robots deployed” appear to misread a 1,000-unit three-year contract in that backlog — see the note on that row.

Boston Dynamics. Reported that Hyundai Motor Group will buy SoftBank’s residual 9.65% for $325M — SoftBank exercising a put option from the 2021 deal. That price implies a ~$3.3bn valuation, so the widely-circulated ~$20bn figure has been removed. We do NOT record the deal as completed: no filing from Hyundai, SoftBank or Boston Dynamics confirms closing, and Hyundai’s Aug 2026 DART half-year report does not name Boston Dynamics.

Semaglutide 25 mg, oral · MHRA. Semaglutide 25 mg, oral: MHRA position recorded as approved · 11 Jun 2026.

NEURA Robotics. Series C of up to $1.4bn, milestone-tranched, from Tether, Qualcomm, Amazon, NVIDIA, Bosch, Schaeffler and the EIB. A $7bn valuation is reported by secondary press and is not in NEURA’s own release — tagged as a claim.

NVIDIA — GR00T reference. Open humanoid reference design published on a Unitree H2 Plus chassis: 31 body DoF plus 22-DoF SharpaWave hands, ~3 h runtime. Added as a reference platform rather than a product.

Kepler Robotics. Downgraded from “mass production” to “pilot”. Takeover filings disclose 2025 revenue of RMB 4.34M against a ~$30,000 list price — roughly 20 robots sold in the year. The implied company valuation of ~RMB 720M is a fraction of its peers.

Compounded GLP-1s. FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would close bulk compounding of all three for good.

Figure AI. Company states 350+ Figure 03 units built at BotQ, at a rate of one robot per hour. Recorded in a separate “units built” note, NOT in the deployed column — Figure publishes production counts but no customer unit counts.

XPeng — IRON. XPeng’s robotics head stated that first-generation dexterous hands failed in under one month of factory trials and that failures came from wiring and signal loss, not AI. Added to the row’s reliability note.

Orforglipron. Approved by FDA as Foundayo — the first small-molecule oral GLP-1. Reviewed in 50 days under the National Priority Voucher programme. Added to the list; the “there is no pill” argument for grey-market buying is now materially weaker.

Orforglipron · FDA. Orforglipron: FDA position recorded as approved · April 2026.

Setmelanotide · EMA. Setmelanotide: EMA position recorded as approved · 27 Mar 2026.

Semaglutide 7.2 mg · FDA. Semaglutide 7.2 mg: FDA position recorded as approved · 19 Mar 2026.

Ecnoglutide. Approved by China's NMPA. Added with the caveat that its pivotal trial has no published sample size and no peer-reviewed publication.

Ecnoglutide · NMPA. Ecnoglutide: NMPA position recorded as approved · 6 Mar 2026.

CagriSema. REDEFINE 4 missed its primary endpoint: CagriSema was not shown non-inferior to tirzepatide head to head. Recorded prominently because consumer coverage of CagriSema has largely omitted it.

Cartwheel Robotics. Shut down. Working toddler-scale home humanoid (Yogi), only $3M raised, no capital partner found to bridge to production. Moved to the graveyard.

Mentee Robotics. Mobileye to acquire for ~$900M. A successful exit, but it removes an independent maker from the field. Status set to “acquired”.

Boston Dynamics — Atlas. Commercial production began at Waltham. First units committed to Hyundai’s Robot Metaplant Application Center and to Google DeepMind; all 2026 output reported as spoken for. Status moved from prototype to pilot.

Semaglutide 7.2 mg · MHRA. Semaglutide 7.2 mg: MHRA position recorded as approved · January 2026.

Oral semaglutide 25 mg. FDA approved the first oral GLP-1 for weight management. Note the estimand gap: the company cites 16.6%, the NEJM primary endpoint is about 14%.

Semaglutide 25 mg, oral · FDA. Semaglutide 25 mg, oral: FDA position recorded as approved · 22 Dec 2025.

Liraglutide 3.0 mg · TGA. Liraglutide 3.0 mg: TGA position recorded as withdrawn · December 2025.

K-Scale Labs. Shut down after failing to find a Series A lead. All K-Bot pre-orders cancelled and refunded; hardware open-sourced under CERN-OHL-S-2.0. Moved to the graveyard.

Mazdutide · NMPA. Mazdutide: NMPA position recorded as approved · 27 Jun 2025.

Tirzepatide · ANVISA. Tirzepatide: ANVISA position recorded as approved · 9 Jun 2025.

Tirzepatide · Canada. Tirzepatide: Canada position recorded as approved · 13 May 2025.

Danuglipron. Pfizer discontinued its oral GLP-1 after a possible drug-induced liver injury — the company's second oral GLP-1 killed by a liver signal.

Tirzepatide · PMDA. Tirzepatide: PMDA position recorded as approved · December 2024.

Tirzepatide · NMPA. Tirzepatide: NMPA position recorded as approved · 19 Jul 2024.

Semaglutide 2.4 mg · NMPA. Semaglutide 2.4 mg: NMPA position recorded as approved · June 2024.

Semaglutide 2.4 mg · TGA. Semaglutide 2.4 mg: TGA position recorded as approved · January 2024.

Tirzepatide · FDA. Tirzepatide: FDA position recorded as approved · 8 Nov 2023.

Tirzepatide · MHRA. Tirzepatide: MHRA position recorded as approved · November 2023.

Semaglutide 2.4 mg · MHRA. Semaglutide 2.4 mg: MHRA position recorded as approved · November 2023.

Semaglutide 2.4 mg · PMDA. Semaglutide 2.4 mg: PMDA position recorded as approved · 10 Mar 2023.

Orlistat · PMDA. Orlistat: PMDA position recorded as approved · January 2023.

Tirzepatide · TGA. Tirzepatide: TGA position recorded as approved · January 2023.

Semaglutide 2.4 mg · ANVISA. Semaglutide 2.4 mg: ANVISA position recorded as approved · January 2023.

Tirzepatide · EMA. Tirzepatide: EMA position recorded as approved · 15 Sep 2022.

Semaglutide 2.4 mg · EMA. Semaglutide 2.4 mg: EMA position recorded as approved · 6 Jan 2022.

Semaglutide 2.4 mg · Canada. Semaglutide 2.4 mg: Canada position recorded as approved · 25 Nov 2021.

Semaglutide 2.4 mg · FDA. Semaglutide 2.4 mg: FDA position recorded as approved · 4 Jun 2021.

Setmelanotide · FDA. Setmelanotide: FDA position recorded as approved · 25 Nov 2020.

Naltrexone / bupropion ER · TGA. Naltrexone / bupropion ER: TGA position recorded as approved · January 2019.

Metreleptin · EMA. Metreleptin: EMA position recorded as approved · 30 Jul 2018.

Naltrexone / bupropion ER · MHRA. Naltrexone / bupropion ER: MHRA position recorded as approved · 26 Mar 2015.

Naltrexone / bupropion ER · EMA. Naltrexone / bupropion ER: EMA position recorded as approved · 26 Mar 2015.

Liraglutide 3.0 mg · MHRA. Liraglutide 3.0 mg: MHRA position recorded as approved · 23 Mar 2015.

Liraglutide 3.0 mg · EMA. Liraglutide 3.0 mg: EMA position recorded as approved · 23 Mar 2015.

Liraglutide 3.0 mg · FDA. Liraglutide 3.0 mg: FDA position recorded as approved · 23 Dec 2014.

Naltrexone / bupropion ER · FDA. Naltrexone / bupropion ER: FDA position recorded as approved · 10 Sep 2014.

Metreleptin · FDA. Metreleptin: FDA position recorded as approved · 24 Feb 2014.

Phentermine / topiramate ER · EMA. Phentermine / topiramate ER: EMA position recorded as refused · 21 Feb 2013.

Phentermine / topiramate ER · FDA. Phentermine / topiramate ER: FDA position recorded as approved · 17 Jul 2012.

Orlistat · TGA. Orlistat: TGA position recorded as approved · January 2000.

Orlistat · FDA. Orlistat: FDA position recorded as approved · 26 Apr 1999.

Orlistat · MHRA. Orlistat: MHRA position recorded as approved · 29 Jul 1998.

Orlistat · EMA. Orlistat: EMA position recorded as approved · 29 Jul 1998.

Phentermine · FDA. Phentermine: FDA position recorded as approved · January 1959.